---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034451"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2024-08-30T23:59:59+00:00"
generated_at: "2026-05-31T06:48:58.724291+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences raises $5M in concurrent registered direct offering and warrant exercise

## Summary
- Gross proceeds of $5M from sale of 3.55M shares (or equivalents) at $0.47 per share and exercise of 7.2M outstanding warrants at reduced price.
- Concurrent private placement of unregistered Series A-3 and A-4 warrants to purchase up to 28.7M shares, exercisable after stockholder approval.
- Net proceeds to fund TAAP and MPAR programs and supplement recently announced $14M NIH grant for PF614-MPAR.
- Existing warrants from November 2023 amended to $0.47 exercise price effective upon closing; stockholder approval required.

## SEC filing metadata
- accession: 0001493152-24-034451
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2024-08-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315224034451/0001493152-24-034451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315224034451/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034451
- JSON: https://secwatch.observer/filing/0001493152-24-034451.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.